Teva Pharmaceutical Industries Ltd. / Novopharm Limited

Multi-Source Generics (Multiple Indications)

Disease Overview

Multi-source generics cover every therapeutic area once branded products lose patent protection. Generic manufacturers compete on ANDA filing depth, manufacturing capacity, supply reliability, and pricing rather than on novel biology.

Competitive Landscape

By 2000, North American generics was the prize battleground for global generic-only manufacturers. Teva entered the deal as a strong but Israel-anchored player; Novopharm, controlled by the Dan Family Holdings, was the second-largest generic manufacturer in Canada with meaningful US and Hungarian (Human Serum & Pharmaceutical) operations. Closest competitors were Mylan, Watson (about to absorb Schein), Ivax, Sandoz/Geneva, and Apotex (the larger Canadian rival). The Novopharm deal — completed April 5, 2000 at >$600M total consideration paid almost entirely in stock — gave Teva a Canadian commercial platform, expanded ANDA pipeline, and a Hungarian manufacturing footprint at a single stroke, lifting Teva to the top of the global generics rankings alongside Sandoz. Strategically, the transaction set the template for Teva's subsequent decade of consolidation (Sicor 2004, Ivax 2006, Barr 2008) that ultimately made it the world's largest generics company. The deal mattered because it converted Teva from a US-focused exporter into a true North American manufacturer with local-market relationships in both Canada and the United States. Source: https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2000/Teva-Announces-Completion-of-Novopharm-Acquisition/default.aspx